Puncture Robotic

Puncture Robotic was founded in 2018, under the medical robotics innovation business direction of Harbin Gongzhong Intelligence (000584.SZ). The company has established an "AI + Image + Robot" technology platform, aiming to address the clinical challenge of the inability to provide real-time imaging guidance for soft tissues. It has developed a range of core technologies including AI-based image recognition and reconstruction, multi-modal image fusion navigation, real-time guidance and tracking, and force feedback control. Its products are applied in several clinical areas such as vascular access applications (vascular puncture robots), tumor interventional biopsy and treatment (fusion navigation puncture robots), block anesthesia (anesthesia robots), and medical aesthetics assistance (Norman robots). The market capacity for these products exceeds tens of billions of dollars. Some products have already entered the NMPA approval process and completed hundreds of human clinical trials. Puncture Robotic advocates a culture of enduring hardships first and enjoying success later, adhering to values of being people-oriented, service-first, actively innovating, and pursuing excellence. It is committed to providing exceptional medical services to humanity through advanced technology, aspiring to become a world-class high-tech medical robotics enterprise.